Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).
Pharmacology, Toxicology and Pharmaceutical Science
2
7%
Biochemistry, Genetics and Molecular Biology
2
7%
Immunology and Microbiology
2
7%
Arts and Humanities
1
3%
Other
1
3%
Unknown
12
41%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 August 2022.
All research outputs
#3,356,381
of 29,868,835 outputs
Outputs from Journal of Clinical Oncology
#8,771
of 27,609 outputs
Outputs of similar age
#60,090
of 452,320 outputs
Outputs of similar age from Journal of Clinical Oncology
#307
of 1,067 outputs
Altmetric has tracked 29,868,835 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 27,609 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.5. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 452,320 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 1,067 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
